Children with hematologic malignancies continue to exhibit increased IPD risk despite an overall decline in pediatric IPD after the introduction of the PCV13 vaccine.

There’s no denying: this is a global health crisis. Between the U.S. cuts and other funding cuts, in total, aid in total has gone down by 30 billion this year alone. It reinforces the incredible ...

Merck MRK announced a definitive agreement to acquire Verona Pharma VRNA for approximately $10 billion. The deal will add ...

While Eli Lilly’s LLY top-line continues to touch new sky highs thanks to its blockbuster GLP-1 medicines — Mounjaro (for ...

A large surveillance study suggests that an extra pneumococcal vaccine dose for new care home residents can significantly ...

Kennedy’s decision to replace ACIP wholesale and the comments he has made about deviating from standard vaccine policymaking ...

A research team has evaluated the real-world impact of a community-based pneumococcal vaccination support program for older ...

CanSinoBIO presents a superior option for preventing pneumococcal diseases in Chinese children. As a leader in innovative vaccines, CanSinoBIO always dedicated to scientific research and ...

As a leader in innovative vaccines, CanSinoBIO always dedicated to scientific research and exploration in vaccine development. The company strives to create innovative, high-quality, and ...

Biological E’s PCV14 – a 14-valent pneumococcal conjugate vaccine, having broad serotype coverage – was found to be non-inferior to Prevenar 13 for all shared serotypes in the pivotal phase ...

Vaxcyte's new pneumococcal vaccine may only have phase 1/2 results behind it, but analysts are already predicting it could be a major competitor to rival shots from Pfizer and MSD. Just-reported ...